And we continue to see momentum for the product. We aspire to become a global leader in this field with Bemiparin and Enoxaparin biosimilar. In this context, we’re investing not only increase ...

J&J seeks preliminary injunction over Samsung's sublicense deal with private label provider J&J says said sublicense deal would hurt its market share Samsung Bioepis launched its biosimilar in U.S ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...

To understand the class of drugs known as biosimilars, it is first necessary to understand the class of drugs described as biologics. Traditionally, biologics were derived through natural ...

Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US.From today, the ...

(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...

Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...

A biosimilar is a biological product that is approved based on data demonstrating that the product is highly similar, with no clinically meaningful differences, to a Food and Drug Administration ...

Laboratorios Farmaceuticos Rovi reported a notable decrease in its financial performance for Q4 2024, with operating revenue falling by 7.9% to 763.7 million euros. Despite the decline, the ...